Pharma BD Deal Intelligence
J&J's $16.6B bet on Impella heart pumps handed it the market-leading platform in mechanical circulatory support, extending its medtech push beyond pharma with a device franchise that had no real competitor at scale.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
J&J acquired Abiomed for $16.6B for cardiovascular medical technology.
Johnson & Johnson completed its acquisition of Abiomed on December 22, 2022, acquiring all outstanding shares for $380 per share in cash for a total equity…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
J&J acquired Abiomed for $16.6B for cardiovascular medical technology.
6.2M US cases/yr · $15.0B Global Heart Failure Device Market (2024)
Cardiogenic shock and acute heart failure require mechanical circulatory support when the heart cannot maintain adequate cardiac output. The Impella platform provides temporary percutaneous ventricular support across a range of devices from 2.5L to 5.5L per minute flow.
Impella is the worlds smallest heart pump, providing minimally invasive cardiac support. Record 60,000 patients treated annually post-J&J acquisition. However, FDA warning letter (Sept 2023) and multiple device recalls have created regulatory concerns about quality systems.
J&J announces $16.6B acquisition of Abiomed to strengthen cardiovascular MedTech portfolio.
J&J acquires Abiomed, maker of Impella heart pumps, as standalone unit within MedTech segment.
Abiomed performance exceeds J&J internal models and Wall Street estimates; strong Impella adoption.
Abiomed operates as standalone within MedTech, maintaining independence while leveraging J&J infrastructure.
Deal becomes earnings accretive in 2024 as projected, after slight dilution in year one.
Abiomed exceeded internal targets in first full year. Standalone model preserves innovation culture.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Abiomed Inc. (this deal) | 2022 | $16.6B | 74 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2022 deals · Johnson & Johnson deals · Cardiovascular deals